Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 15

recruiting
3 968
countries
28
conditions
2 103

245 trials match your criteria

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine

Major depression

Not recruiting

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Nelivaptan

Plasma cell myeloma

Not recruiting

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Danazol

Factor VIII deficiency+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab

Hormone-refractory prostate cancer

Not recruiting

Study Comparing Radium-223 Dichloride with Abiraterone Acetate, Enzalutamide, and Prednisone in Patients with Advanced Prostate Cancer Spread to the Bone

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.